Public Employees Retirement System of Ohio Invests $2.84 Million in Qiagen N.V. $QGEN

Public Employees Retirement System of Ohio acquired a new position in shares of Qiagen N.V. (NYSE:QGEN) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 72,503 shares of the company’s stock, valued at approximately $2,836,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Danske Bank A S acquired a new stake in Qiagen during the 3rd quarter valued at $36,000. Manchester Capital Management LLC acquired a new position in shares of Qiagen in the fourth quarter worth $42,000. Hilltop National Bank purchased a new stake in shares of Qiagen in the second quarter valued at $50,000. Global Retirement Partners LLC lifted its position in shares of Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after acquiring an additional 851 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new stake in shares of Qiagen during the third quarter valued at $64,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the stock a “hold” rating in a research note on Thursday, June 25th. Citigroup reiterated a “neutral” rating and set a $45.00 price target (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Barclays set a $40.00 price objective on shares of Qiagen and gave the company an “equal weight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised shares of Qiagen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $43.93.

Qiagen Price Performance

Qiagen stock opened at $43.36 on Friday. Qiagen N.V. has a 1 year low of $32.53 and a 1 year high of $57.81. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The firm has a 50 day moving average price of $41.91 and a 200 day moving average price of $40.41. The company has a market cap of $8.94 billion, a price-to-earnings ratio of 22.22, a PEG ratio of 4.33 and a beta of 0.63.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. Qiagen’s revenue was up .2% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts predict that Qiagen N.V. will post 2.43 earnings per share for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.